Vericel Corp Ord (VCEL)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $2.91B
Last updated: Nov 17, 2026 at 11:05 AM ET
Vericel Corp Ord (VCEL) P/E Ratio & Valuation History
Vericel Corp Ord (VCEL) trades at 89.8x trailing earnings and 9.1x sales. Its P/S of 9.1x is above its 5-year median of 8.7x. Its forward P/E is 63.7x.
Current Multiples
Its forward P/E is below its trailing P/E, which implies earnings per share about 41.0% higher over the next year. Its free cash flow yield is 2.0%.
| Multiple | Value |
|---|---|
| P/E (trailing) | 89.8x |
| Forward P/E | 63.7x |
| Price to sales | 9.1x |
| Price to book | 7.7x |
| EV/EBITDA | 69.0x |
| Price to FCF | 50.8x |
| EV/FCF | 48.5x |
| PEG | N/A |
| FCF yield | 2.0% |
Historical Medians
Against its 10-year medians, its P/S is 18.2% above 7.7x and its P/B is 1.3% below 7.8x.
| Multiple | Current | 5-year median | 10-year median |
|---|---|---|---|
| P/S | 9.1x | 8.7x | 7.7x |
| P/B | 7.7x | 7.7x | 7.8x |
Valuation History
Over the 4 of the 10 year ends shown that have a P/E, its P/E ranged from 116.0x in 2019 to 617.6x in 2020.
| Year end | Price | P/E | P/S | P/B |
|---|---|---|---|---|
| 2025 | $36.01 | 116.2x | 6.6x | 5.3x |
| 2024 | $54.91 | 305.1x | 11.5x | 9.8x |
| 2023 | $35.61 | N/A | 8.7x | 8.0x |
| 2022 | $26.34 | N/A | 7.7x | 6.7x |
| 2021 | $39.30 | N/A | 11.9x | 11.5x |
| 2020 | $30.88 | 617.6x | 11.5x | 11.1x |
| 2019 | $17.40 | 116.0x | 6.6x | 7.3x |
| 2018 | $17.40 | N/A | 7.9x | 7.9x |
| 2017 | $5.45 | N/A | 2.9x | 8.7x |
| 2016 | $3.00 | N/A | 1.3x | 3.0x |
GNG Valuation
| GNG view | Undervalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About VCEL
What is VCEL's forward P/E ratio?
Vericel Corp Ord has a forward P/E ratio of 63.7x.
Is VCEL stock overvalued?
GNG's valuation label for VCEL is Undervalued.
What is VCEL's price to sales ratio?
Vericel Corp Ord has a price to sales ratio of 9.1x.
VCEL pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors